Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
World Journal of Psychiatry May 19, 2023 Lakshan N Fonseka, Benjamin K.p. Woo 12 citations
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression, psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched, rapid improvement in a multitude of psychiatric conditions....